Risk Stratified Sequential Treatment for CD20-positive PTLD
NCT00590447
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
152
Enrollment
OTHER
Sponsor class
Conditions
PTLD
Posttransplant Lymphoproliferative Disorder
Interventions
DRUG:
rituximab monotherapy
DRUG:
sequential R-CHOP
Sponsor
Charite University, Berlin, Germany